HOME >> BIOLOGY >> NEWS
Scientists follow familiar TRAIL to new cancer therapy

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor (TNF) death receptor ligand against a variety of human cancers.

Potency and lack of toxicity to normal tissues make activation of TNF-a-related apoptosis-inducing ligand (TRAIL) death receptor signaling an attractive and exciting target for cancer therapy, and it is currently being tested in clinical trials. However, most cancer cells have defects in their ability to die via a cell death pathway called apoptosis, and unfortunately, TRAIL therapy is not effective in cells that have certain defects in apoptotic pathways. Dr. Wafik S. El-Deiry from the University of Pennsylvania School of Medicine and colleagues designed a series of studies to gain a better understanding of TRAIL-associated cell signaling pathways in cancer cells and to look for ways to pharmacologically optimize TRAIL therapy.

Dr. El-Deirys group had previously established that c-Myc is a key mediator of TRAIL-induced apoptosis and that cancer cells lacking c-Myc and a functional apoptotic pathway were resistant to TRAIL. In the current study, the researchers demonstrated that expression of c-Myc in TRAIL-resistant human colon cancer cells sensitized the cells to TRAIL, even when the cells had intrinsic apoptotic defects. The researchers observed that TRAIL induced expression of two potent antiapoptotic molecules, Mcl-1 and cIAP2, and that c-Myc repressed both molecules.

The researchers also discovered that the multikinase inhibitor sorafenib prevented TRAIL-mediated induction of Mcl-1 and cIAP2, and although it had little effect on the killing of TRAIL-resistant cells when administered alone, combination with TRAIL caused
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Jul-2007


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2020)... , ... April 27, 2020 , ... ... category-defining service was started by three teenagers with an idea to help millions ... world during the time of great need and suffering, an outlet has been ...
(Date:4/23/2020)... Wis. (PRWEB) , ... April 23, 2020 , ... ... its expansion and recruitment plans. MDG provides critical infrastructure products for the animal ... push MDG’s previous plans for expansion. Further, as supply channels from overseas competitors ...
(Date:4/22/2020)... Calif. (PRWEB) , ... April 21, 2020 , ... ... driving digital transformation and innovation in technology and compliance, announces a new managed ... a best-in-class trio of alliances – Box, ComplianceQuest, and USDM Life Sciences (USDM) ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... ... 13, 2020 , ... Early stages of drug discovery often ... information on the drug’s mechanism of action (MOA). Gene expression profiling technologies like ... activity of molecular pathways. This information can complement phenotypic readouts and can be ...
(Date:5/5/2020)... , ... May 05, 2020 , ... ... company, announced today the launch of its iGlucose® LTE Cat-M Cellular ... solution utilizes LTE Cat-M1 technology, the industry’s newest and broadest cellular connectivity available, ...
(Date:4/22/2020)... BUDAPEST, Hungary and CAMBRIDGE, Mass. (PRWEB) , ... ... ... headquartered in Budapest with US offices in Cambridge, MA, announced today that Omixon’s ... Meintjes led the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 ...
(Date:4/7/2020)... ... 06, 2020 , ... Gateway Genomics , leading developer of direct-to-consumer genetic ... Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark ... where a mom could order her kit online, collect a DNA sample from her ...
Breaking Biology Technology:
Cached News: